Recent Understanding and Future Directions in the Application of MMP-2 in Encapsulating Peritoneal Sclerosis Clinical Practice

Yaxuan Fang; Xin Chen; Ke Zhong; Qingying Ni; Zhenyang He; Yanheng Qiao; Yanru Zhao; Jie Li; Hongtao Yang; Bo Yang

doi:10.1159/000528001

Recent Understanding and Future Directions in the Application of MMP-2 in Encapsulating Peritoneal Sclerosis Clinical Practice

Blood Purif. 2023;52(4):359-365. doi: 10.1159/000528001. Epub 2023 Jan 4.

Authors

Yaxuan Fang^{1

2}, Xin Chen^{1

2}, Ke Zhong^{1

2}, Qingying Ni^{1

2}, Zhenyang He^{1

2}, Yanheng Qiao^{1

2}, Yanru Zhao^{1

2}, Jie Li^{1

2}, Hongtao Yang^{1

2}, Bo Yang^{1

2}

Affiliations

¹ Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
² Department of Nephrology, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.

PMID: 36599318
DOI: 10.1159/000528001

Abstract

Encapsulating peritoneal sclerosis (EPS) is an uncommon and harmful complication which may cause destructive outcomes. Matrix metalloproteinase-2 (MMP-2) as a protease can reduce constituents of the extracellular matrix and play a crucial role in the progression of EPS. As a new biomarker, MMP-2 may improve the detection rate of EPS patients in clinical work. In this review, we summarize the recent study of MMP-2 in different etiologies and the assessment of its application value and draw attention to its future directions.

Keywords: Biomarkers; Encapsulating peritoneal sclerosis; Matrix metalloproteinase-2; Peritoneal dialysis; Peritoneal injury.

Publication types

Review

MeSH terms

Biomarkers
Humans
Matrix Metalloproteinase 2
Peritoneal Dialysis* / adverse effects
Peritoneal Fibrosis* / etiology
Peritoneum / pathology

Substances

Matrix Metalloproteinase 2
Biomarkers